Spectrum Pharmaceuticals Inc.

06/22/2021 | Press release | Distributed by Public on 06/22/2021 14:20

Submission of Matters to a Vote of Security Holders (Form 8-K)

Submission of Matters to a Vote of Security Holders.

Spectrum Pharmaceuticals, Inc. (the 'Company') held its 2021 annual meeting of stockholders (the 'Annual Meeting') on June 17, 2021 at the Company's corporate headquarters located at 11500 S. Eastern Avenue, Suite 240, Henderson, Nevada 89052. As of the close of business on April 20, 2021, the record date for the Annual Meeting, a total of 155,713,230 shares were outstanding and entitled to vote, of which a total of 106,681,573 shares were present in person or by proxy at the Annual Meeting, constituting a quorum for the conduct of business thereat.

The following sets forth detailed information regarding the voting results at the Annual Meeting for each of the matters voted upon by the stockholders. These matters are described in more detail in the Company's Definitive Proxy Statement for its Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 21, 2021 (the 'Proxy Statement').

Proposal No. 1:
The Company's stockholders elected each of the seven nominees named below to serve on the Board of Directors of the Company for a one-year term expiring at the annual meeting of stockholders in 2022 and until their respective successors are duly elected and qualified, or until their earlier resignation or removal.

Nominee Votes For Votes Against Abstentions Broker Non-Votes
William L. Ashton 83,591,525 2,264,965 457,988 20,367,095
Nora E. Brennan 84,250,330 1,637,135 427,013 20,367,095
Seth H.Z. Fischer 83,679,081 2,185,138 450,259 20,367,095
Joseph W. Turgeon 84,018,497 1,866,293 429,688 20,367,095
Jeffrey L. Vacirca, M.D., FACP 83,048,340 2,782,897 483,241 20,367,095
Dolatrai M. Vyas, Ph.D. 83,565,401 2,297,537 451,540 20,367,095
Bernice R. Welles, M.D., M.B.A. 83,002,308 2,884,751 427,419 20,367,095

Proposal No. 2:
The Company's stockholders approved by advisory vote the compensation of the Company's named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
Votes For Votes Against Abstentions Broker Non-Votes
81,208,187 4,439,741 666,550 20,367,095

Financial Statements and Exhibits.
(d) Exhibits

Exhibit No. Description
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)